Product Information
BUMETANIDE 2 MG TABLET is a generic product labeled by Upsher-Smith Laboratories LLC, priced at $0.1819 per EA under NDC 00832054211. Its NADAC has been published 448 times since Mar 7, 2018.
FDA first approved this application on Jan 23, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
2 mg/1
Manufacturer
Upsher-Smith Laboratories LLCNDC
00832054211
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
BUMETANIDEApproval Type
Generic (ANDA)
FDA Application
ANDA209916FDA Approved
1/23/2018
TE Code
AB
On Market Since
1/30/2018
Pharmacological Classes
Price Statistics
The NADAC for BUMETANIDE 2 MG TABLET has been published 448 times since Mar 7, 2018, and over the history we have for it it has declined 81.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1819 per EA |
|---|---|
| All-time high | $1.0081 (Apr 11, 2018) |
| All-time low | $0.1717 (Jul 22, 2026) |
| 52-week high | $0.2384 |
| 52-week low | $0.1717 |
| Median price | $0.4059 |
| Average price | $0.4767 |
| Largest weekly change | +35.6% (Jun 19, 2024) |
| Weeks tracked | 448 |
| Tracking since | Mar 7, 2018 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the BUMETANIDE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Upsher-Smith Laboratories LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
BUMETANIDE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Loop Diuretic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BUMETANIDE 2 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for BUMETANIDE 2 MG TABLET, manufactured by Upsher-Smith Laboratories LLC, is $0.1819 per EA (NDC 00832054211), effective Sep 30, 2026.
How has the price of BUMETANIDE 2 MG TABLET changed over time?
Over the history we have for it, the NADAC for BUMETANIDE 2 MG TABLET has declined 81.7%. It has been tracked across 448 weekly CMS publications since Mar 7, 2018.
What are the highest and lowest recorded NADAC prices for BUMETANIDE 2 MG TABLET?
Since Mar 7, 2018, the NADAC for BUMETANIDE 2 MG TABLET has ranged from a low of $0.1717 (Jul 22, 2026) to a high of $1.0081 (Apr 11, 2018), with a median of $0.4059 per EA.
Are there cheaper alternatives to BUMETANIDE 2 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of BUMETANIDE 2 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures BUMETANIDE 2 MG TABLET?
BUMETANIDE 2 MG TABLET (NDC 00832054211) is labeled by Upsher-Smith Laboratories LLC, and CMS classifies it as a generic product.